Skip to content
Open access · CC-BY via OpenAlex

Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy

Dekun Liu, Napamanee Kornthong, Shuguang Yu, Jakkree Tangthianchaichana, Prasert Sobhon, Sha Yang

Cardiology Research and Practice · 2026

Abstract

Atherosclerosis underlies most ischemic cardiovascular events, and its prevalence rises with population aging. Cellular senescence(definition) is increasingly implicated as a driver of plaque progression, although the causal evidence is largely preclinical. Senescent endothelial cells, smooth muscle cells, and macrophages acquire a senescence‐associated secretory phenotype (SASP), releasing cytokines, chemokines, proteases, and procoagulant factors. These factors sustain plaque inflammation, weaken the fibrous cap, and increase rupture risk. In this narrative review, we link SASP signaling to plaque instability through NF‐κB, p38 MAPK, mTOR(definition), NLRP3, and cGAS–STING signaling. We then evaluate tetramethylpyrazine (ligustrazine), quercetin, fisetin, resveratrol, and curcumin against an operational definition reserving senolytic and senomorphic for effects shown in confirmed senescent cells. On that standard, only quercetin and fisetin qualify; for the other three, the vascular evidence is anti‐inflammatory, antioxidant, or senescence‐preventive rather than directed at established senescent cells. Tetramethylpyrazine protects the endothelial glycocalyx and reduces plaque area in atherosclerotic rabbits. Dasatinib plus quercetin benefits ApoE−/− mice, whereas the only human evidence comes from quercetin monotherapy, which improved endothelium‐dependent vasodilation in vessels from symptomatic male, but not female, bypass patients ex vivo. Because senescence burden varies between individuals, we consider how multiomics profiling might stratify patients. The evidence remains mechanistic and hypothesis‐generating, with limited human cardiovascular interventional data: Much of it was recorded in cells never shown to be senescent, and no formulation has been shown to reach the human vessel wall. Targeting the SASP therefore requires trial evidence rather than an established basis for precision medicine.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1155/crp/6765242
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Liu, D., Kornthong, N., Yu, S., Tangthianchaichana, J., Sobhon, P., &amp; Yang, S. (2026). Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy. <em>Cardiology Research and Practice</em>. https://doi.org/10.1155/crp/6765242
Vancouver
Liu D, Kornthong N, Yu S, Tangthianchaichana J, Sobhon P, Yang S. Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy. Cardiology Research and Practice. 2026. doi:10.1155/crp/6765242.
BibTeX
@article{dekun2026Senesc, title = {Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy}, author = {Dekun Liu and Napamanee Kornthong and Shuguang Yu and Jakkree Tangthianchaichana and Prasert Sobhon and Sha Yang}, journal = {Cardiology Research and Practice}, year = {2026}, doi = {10.1155/crp/6765242}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings